Literature DB >> 2407492

Vascular haemodynamic effects of perindopril in essential hypertension.

W Littler1.   

Abstract

Perindopril is an orally active non-thiol angiotensin-converting enzyme (ACE) inhibitor that is hydrolysed by esterases to a biologically active diacid metabolite. Perindopril decreases plasma concentrations of angiotensin II, increases plasma renin activity and reduces systolic and diastolic blood pressure in patients with essential hypertension. Most data support the hypothesis that the beneficial haemodynamic effects of perindopril are caused by ACE inhibition and the consequent reduction in angiotensin II, which either directly or indirectly results in dilatation of peripheral vessels and reduced vascular resistance. The marked blood pressure reduction after perindopril administration in hypertensive patients has not been accompanied by significant changes in heart rate. Furthermore, the lack of reflex tachycardia does not appear to be related to a reduction in baroreceptor sensitivity.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2407492     DOI: 10.2165/00003495-199000391-00008

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  13 in total

1.  The haemodynamic and humoral effects of treatment for one month with the angiotensin converting enzyme inhibitor perindopril in salt replete hypertensive patients.

Authors:  K R Lees; J L Reid
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

2.  Baroreflex setting and sensitivity in normal subjects: effects of pharmacologic inhibition of the angiotensin I converting enzyme.

Authors:  R Düsing; G Kayser; S Wagner; H Scherf; K Glänzer; H G Predel; H J Kramer
Journal:  Am J Cardiol       Date:  1987-04-24       Impact factor: 2.778

Review 3.  Enalapril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure.

Authors:  P A Todd; R C Heel
Journal:  Drugs       Date:  1986-03       Impact factor: 9.546

4.  Inhibition of angiotensin I-converting enzyme with S 9490: biochemical effects, interspecies differences, and role of sodium diet in hemodynamic effects.

Authors:  M Laubie; P Schiavi; M Vincent; H Schmitt
Journal:  J Cardiovasc Pharmacol       Date:  1984 Nov-Dec       Impact factor: 3.105

5.  Baroreflex setting and sensitivity after acute and chronic nicardipine therapy.

Authors:  M A Young; R D Watson; W A Littler
Journal:  Clin Sci (Lond)       Date:  1984-02       Impact factor: 6.124

6.  Evidence that the acute hypotensive effect of captopril in dogs is not wholly explained by a reduction of plasma angiotensin II and its direct vasoconstrictor effect.

Authors:  M Tree; J J Morton
Journal:  Clin Sci (Lond)       Date:  1980-12       Impact factor: 6.124

Review 7.  Captopril: a preliminary review of its pharmacological properties and therapeutic efficacy.

Authors:  R C Heel; R N Brogden; T M Speight; G S Avery
Journal:  Drugs       Date:  1980-12       Impact factor: 9.546

8.  Captopril in clinical hypertension. Changes in components of renin-angiotensin system and in body composition in relation to fall in blood pressure with a note on measurement of angiotensin II during converting enzyme inhibition.

Authors:  A B Atkinson; J J Morton; J J Brown; D L Davies; R Fraser; P Kelly; B Leckie; A F Lever; J I Robertson
Journal:  Br Heart J       Date:  1980-09

9.  Modification of arterial baroreflexes by captopril in essential hypertension.

Authors:  G Mancia; G Parati; G Pomidossi; G Grassi; G Bertinieri; N Buccino; A Ferrari; L Gregorini; L Rupoli; A Zanchetti
Journal:  Am J Cardiol       Date:  1982-04-21       Impact factor: 2.778

10.  Effects of perindopril on ambulatory intra-arterial blood pressure, cardiovascular reflexes and forearm blood flow in essential hypertension.

Authors:  J N West; S A Smith; T J Stallard; W A Littler
Journal:  J Hypertens       Date:  1989-02       Impact factor: 4.844

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.